Dr. Lee F. Allen joined AMAG Pharmaceuticals in August 2007. Dr. Allen is responsible for the Company's clinical development and regulatory activities and also leads the continued advancement of the Company's drug and imaging development strategies.

Prior to joining AMAG Pharmaceuticals, Dr. Allen was at Wyeth Pharmaceuticals, where he was Site Head for Wyeth's Cambridge R&D facility, Vice President of Clinical Research and Development, and the head of the Oncology therapeutic area. Before joining Wyeth, he held positions of increasing responsibility at Pfizer and BASF's Knoll Pharmaceutical Company. Prior to entering the pharmaceutical industry in 1997, he was a faculty member at Duke University Medical Center and at the University of Utah's Huntsman Cancer Institute.

Dr. Allen received his PhD and subsequently his MD from the University of Medicine and Dentistry of New Jersey. His work has been published in several scientific journals including the Proceeding of the National Academy of Sciences, Nature and Science.